In non-infectious liver diseases (e.g., PBC), CX3CL1/Fractalkine perpetuates the autoimmune progression of the diseases via TLR-based mechanisms and the recruitment of adaptive immunity cells [26]. Here, CX3CL1 is linked to primary biliary cholangitis.